Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147721 | 1.00 | LMNA (0.54) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL17108622 | 1.00 | LMNA (0.54) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL13296277 | 1.00 | LMNA (0.54) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL13893284 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL13314743 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL14147722 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL17108604 | 0.94 | LMNA (0.61) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL810658 | 0.92 | TDP1 (0.63) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL3138410 | 0.92 | TDP1 (0.63) | LMNAL3MBTL1TDP1TSHRKDM4E | |
| SCHEMBL18744680 | 0.92 | TDP1 (0.63) | LMNAL3MBTL1TDP1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368983-A1 | CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS | KAPA BIOSYSTEMS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4581153-A1 | IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE | F. Hoffmann-La Roche AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| EP-4547839-A1 | CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS | Kapa Biosystems, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119895049-A | Improvements to next generation target enrichment performance | 豪夫迈·罗氏有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119497755-A | Control of library insert size for fragmentation and tag sequencing using archaebacteria histone-like proteins | 卡帕生物系统公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024046992-A1 | IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE | F. HOFFMANN-LA ROCHE AG (CH) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024003332-A1 | CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-04 | — | — | WO | disclosed |
| CN-115184120-A | Fixative composition for cell-containing liquid samples | 凯杰有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3149446-B1 | FIXATIVE COMPOSITION FOR CELL-COMPRISING LIQUID SAMPLES | QIAGEN GMBH (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-20210389216-A1 | FIXATION OF A BIOLOGICAL MATERIAL | QIAGEN GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| US-8415387-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100261863-A1 | MULTIBRANCHED POLYOXYALKYLENE COMPOUND AND PRODUCING METHOD THEREOF | NOF CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100173295-A1 | FIXATION OF A BIOLOGICAL MATERIAL | QIAGEN GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100009349-A1 | Method for Treating a Biological Sample | QIAGEN GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2007077199-A9 | A METHOD FOR TREATING A BIOLOGICAL SAMPLE | QIAGEN GMBH (DE) | 2008-12-11 | — | — | WO | disclosed |
| EP-1969341-A2 | A METHOD FOR TREATING A BIOLOGICAL SAMPLE | Qiagen GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1965190-A1 | Fixation of a biological sample | Qiagen GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007077199-A2 | A METHOD FOR TREATING A BIOLOGICAL SAMPLE | QIAGEN GMBH (DE) | 2007-07-12 | — | — | WO | disclosed |
| EP-1804045-A1 | Method for treating a biological sample | Qiagen GmbH (DE) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | LMNA 2078/4885L3MBTL1 4609/4885TDP1 4520/4885 |
| US-20100261863-A1 | MULTIBRANCHED POLYOXYALKYLENE COMPOUND AND PRODUCING METHOD THEREOF | OPRM1, AOC2, OPRK1 | LMNA 3437/4885L3MBTL1 175/4885TDP1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.